Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $18 to $19.
Benzinga23 days agoBHVN
RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23
RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.
Benzinga24 days agoBHVN
Biohaven Q2 Adj. EPS $(0.78) Misses $(0.73) Estimate
Biohaven (NYSE:BHVN) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.73) by 6.85 percent. This is a 52.15 percent increase over losses of $(1.63) per share from the same
Benzinga25 days agoBHVN